文献速递围术期管理与 ERAS

三种机器人平台在微创机器人辅助子宫切除术中的前瞻性比较研究

Da Vinci® X™, Versius®, and Hugo™ RAS in minimally invasive robotic-assisted hysterectomy: the COMPAR-HYST prospective study.
PubMed 文献 · Surg Endosc · 2026-06-10

COMPAR-HYST前瞻性非随机研究比较da Vinci X、Versius与Hugo RAS三种机器人平台在子宫切除术中的表现。结果显示总体手术表现无差异,Hugo失血量低于da Vinci X,Hugo与Versius术后第三天疼痛低于da Vinci X,但耗材与平台相关成本存在显著差异。

要点

  • 三平台总体手术表现(optimal hysterectomy)无显著差异。
  • Hugo较da Vinci X失血量少72 mL,术后第三天疼痛更低。
  • 每次手术总成本da Vinci X最高,Versius最低。

核心结论

  • 三种机器人平台在子宫切除术中表现出相似的手术表现与安全性,仅存在微小差异。
  • 机器人系统相关费用仍是该术式的主要成本,耗材与平台相关成本间存在差异。

研究设计与样本

  • 前瞻性单中心非随机研究,纳入2024年1月至12月连续成人女性择期腹腔镜子宫切除术患者。
  • 按手术当日平台可用性1:1:1分配至三种机器人平台,每个平台最多50例手术。
  • 主要结局为optimal hysterectomy复合指标、围术期结局及成本。

主要发现

  • optimal hysterectomy在da Vinci X、Hugo、Versius分别达29%、32%、24%(p=0.735)。
  • Hugo较da Vinci X术中失血量少72 mL(95%CI -114, -29;p=0.001)。
  • Hugo(-1.1;95%CI -2.1, -0.17;p=0.012)与Versius(-1.4;95%CI -2.4, -0.43;p<0.01)术后第三天疼痛评分均低于da Vinci X。
  • 手术时间与故障等其他围术期结局无差异。
  • 平台相关间接成本:da Vinci X €1550.43、Hugo €1748.18、Versius €1847.47;加入耗材后每例总成本分别为€5048.46、€3334.18、€2921.07(p<0.001)。

临床怎么用

  • 选择机器人平台时需综合考虑失血量、术后疼痛及耗材与平台相关成本差异。
  • Hugo平台在失血量与术后疼痛方面可能具有优势,但平台相关间接成本较高。
  • da Vinci X耗材加入后每例总成本最高,Versius最低。

局限性

  • 单中心非随机设计,平台分配基于手术当日可用性。
  • 每个平台最多50例手术,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To compare the da Vinci® X™ (Intuitive Surgical), Versius® (CMR Surgical), and Hugo™ RAS (Medtronic) robotic platforms for the procedure of hysterectomy. DESIGN: Prospective single-center non-randomized study. SETTING: Referral center for gynecologic surgery. POPULATION: All consecutive adult women scheduled for elective laparoscopic hysterectomy between January and December 2024 were eligible. METHODS: Enrolled patients were assigned to one of the three robotic platforms (1:1:1) based on the availability on the day of surgery, with a maximum of 50 procedures per platform. MAIN OUTCOME MEASURES: Optimal hysterectomy (composite outcome for performance), perioperative outcomes, and costs. RESULTS: The overall performance did not differ, with an optimal hysterectomy achieved in 29, 32, and 24% of cases with da Vinci X, Hugo, and Versius, respectively (p = 0.735). Intraoperative blood loss was associated with uterine weight and robotic platform (Hugo reported lower blood loss than da Vinci X (- 72 mL; 95%CI - 114, - 29; p = 0.001); both Hugo (- 1.1; 95%CI - 2.1, - 0.17; p = 0.012) and Versius (- 1.4; 95%CI - 2.4, - 0.43; p < 0.01) provided lower pain on postoperative day three than da Vinci X. Other perioperative outcomes (i.e., operative times and malfunctions) did not differ. Platform-related indirect costs averaged €1550.43 for da Vinci X, €1748.18 for Hugo, and €1847.47 for Versius; when consumables were added, the cost per procedure was €5048.46, €3334.18, and €2921.07, respectively (p < 0.001). CONCLUSIONS: The three robotic platforms exhibited similar performance and safety, with minor differences. The expenses related to the robotic system remain the most relevant for the procedure, with differences between robotic consumables and platform-related costs. TRIAL REGISTRATION: NCT06138197.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Garzon S, Landi S, Da Ros A, et al. Da Vinci® X™, Versius®, and Hugo™ RAS in minimally invasive robotic-assisted hysterectomy: the COMPAR-HYST prospective study. Surg Endosc. 2026. PMID: 42268383. doi:10.1007/s00464-026-12873-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。